ClinicalTrials.gg
RecruitingNCT07601334Updated Sep 28, 2026

Safety and Activity of HF50 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HF50 in Advanced Solid Tumors, sponsored by HighField Biopharmaceuticals Corporation. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by HighField Biopharmaceuticals Corporation · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Sep 28, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.

Read the detailed description

This is an open-label, dose-escalation and dose-expansion, multiple-dose, phase 1 study evaluating HF50 monotherapy in participants with advanced solid tumors. HF50 is an innovative liposome-encapsulated T-cell engager designed to redirect T-cells to tumor cells by presenting both tumor-associated antigen (e.g., HER2) and CD3 targeting moieties on the liposome surface. Simultaneously, HF50 delivers an encapsulated TLR7/8 agonist to activate innate immunity and remodel the tumor immune microenvironment, creating a synergistic anti-tumor immune response.The primary objective is to evaluate the safety and tolerability of HF50 and to determine the recommended Phase 2 dose (RP2D). HF50 will be administered as an intravenous (IV) infusion. The study will also assess the pharmacokinetic (PK) profile, immunogenicity, and preliminary anti-tumor activity of HF50. Additionally, the study will explore the impact of HF50 on the immune microenvironment and changes in peripheral blood cytokines and immune cells to better understand its biological effects.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

HighField Biopharmaceuticals Corporation is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation: Capable of giving signed and able to comply with all study-related procedures.
  • Age: Adults >= 18 years of age at the time of signing informed consent; male or female.
  • Disease Status: Participants with or cytologically confirmed advanced solid tumors that are unresectable or , who have failed or are intolerant to standard therapies, or for whom no effective therapy currently exists. Examples include -expressing gynecological tumors and recurrent ovarian clear cell carcinoma after failure of platinum-based chemotherapy.
  • Performance Status: (ECOG) performance status score of 0 to 1.
  • : Anticipated survival of no less than 6 months.
  • : At least one measurable lesion according to v1.1 definitions.
  • Organ and Bone Marrow Function:

Bone Marrow Reserve: (ANC) >= 1.5 x 10\^9/L, lymphocyte count >= 1.0 x 10\^9/L, count >= 90 x 10\^9/L, and >= 9.0 g/dL (no blood transfusion or hematopoietic stimulators within 14 days).

Coagulation Function: (APTT) \<= 1.5 x , and International Normalized Ratio (INR) \<= 1.5.

Liver Function: Total (TBIL) \<= 1.5 x ULN, and and AST \<= 2.5 x ULN. For participants with liver metastases: ALT and AST \<= 5 x ULN, and TBIL \<= 3 x ULN.

Renal Function: >= 50 mL/min (calculated using the Cockcroft-Gault formula).

  • : Participants of (including males) must agree to use effective contraception from study entry through 6 months after the last dose. Female participants of must have a negative serum pregnancy test during screening and prior to the first dose.

Exclusion criteria

Exclusion Criteria:

  • Disease: Any active autoimmune disease or history of autoimmune disease deemed unsuitable by the investigator. Exceptions include skin conditions not requiring systemic treatment (e.g., eczema \< 10% of body surface area, vitiligo, psoriasis, alopecia) and resolved childhood asthma.
  • /: Current use of immunosuppressants or systemic corticosteroids (> 10 mg/day prednisone or equivalent) within 4 weeks prior to the first dose. Topical steroid use is permitted.
  • Prior Anti-tumor Therapy: Receipt of systemic chemotherapy, radiotherapy, targeted therapy, or immunotherapy within 2 weeks prior to dosing (4 weeks for nitrosoureas or mitomycin C); or other therapies (endocrine therapy, TCM, localized palliative radiotherapy) within 2 weeks.
  • : Clinically symptomatic brain or meningeal . Participants with treated brain metastases are eligible if radiographic stability is maintained for >= 28 days, systemic steroids have been discontinued for > 14 days, and the participant is asymptomatic.
  • Toxicity Recovery: Failure to recover from all adverse events of prior therapies to \<= Grade 1 ( v5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, or stable hypothyroidism on hormone replacement.
  • Cardiovascular History: Including thromboembolic events within 3 months; Class III to IV congestive heart failure; acute coronary syndrome, aortic dissection, stroke, or other Grade >= 3 cardiovascular events within 6 months; or uncontrolled hypertension (SBP > 160 mmHg or DBP > 100 mmHg).
  • Infection: Active infection or unexplained fever > 38.5 degrees C within 1 week prior to the first dose (tumor-related fever is permitted per investigator judgment).
  • Viral Infection: infection, active (HBV DNA > ), or active (HCV RNA > ULN).
  • Gastrointestinal Symptoms: Significant digestive system symptoms or other factors requiring intervention within 4 weeks prior to the first dose.
  • Pregnancy/Lactation: Female participants who are pregnant or breastfeeding.
  • Other: Any other serious systemic disease or reason that, in the investigator's opinion, makes the participant unsuitable for the study.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    HF50

    HF50 monotherapy

    Drug: HF50

Interventions

  • DrugHF50

    HF50 is an innovative liposome-encapsulated bifunctional therapeutic designed to redirect T-cells to HER2-expressing tumor cells while simultaneously activating innate immunity through TLR7/8 agonism.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicities (DLT)

    The number of participants experiencing dose-limiting toxicities (DLTs) during the DLT evaluation period to determine the maximum tolerated dose (MTD).

    Time frame: 28 days after the first dose (C1D1) for each dose cohort.

  2. Incidence of Adverse Events (AEs)

    The number and percentage of participants experiencing adverse events (AEs), graded according to NCI-CTCAE v5.0

    Time frame: From first dose to 28 days after the last dose.

  3. Recommended Phase II Dose (RP2D) of HF50

    RP2D will be determined based on safety, tolerability, and pharmacokinetics data collected during the dose escalation phase.

    Time frame: At the end of dose escalation (assessed up to 1 year)

Secondary outcomes

  1. Objective Response Rate (ORR)

    Proportion of participants achieving a complete response (CR) or partial response (PR) based on RECIST v1.1 criteria.

    Time frame: Up to 2 years

  2. Duration of Response (DOR)

    Time from the first documented response (CR or PR) to disease progression or death.

    Time frame: Up to 2 years

  3. Disease Control Rate (DCR)

    Proportion of participants achieving CR, PR, or stable disease (SD) based on RECIST v1.1.

    Time frame: Up to 2 years

  4. Progression-Free Survival (PFS)

    Time from the first dose to disease progression or death.

    Time frame: Up to 2 years

  5. Overall Survival (OS)

    Time from the first dose to death from any cause.

    Time frame: Up to 2 years

  6. Pharmacokinetic Parameter - Cmax

    Maximum plasma concentration (Cmax) of HF50 will be assessed following single and multiple dosing.

    Time frame: Up to 2 years

  7. Pharmacokinetic Parameter - Tmax

    Time to maximum plasma concentration (Tmax) of HF50 will be assessed following single and multiple dosing.

    Time frame: Up to 2 years

  8. Pharmacokinetic Parameter - AUC (Area Under the Curve)

    AUC0-t and AUC0-inf will be evaluated to determine systemic exposure to HF50.

    Time frame: Up to 2 years

  9. Pharmacokinetic Parameter - Half-life (t1/2)

    The terminal elimination half-life (t1/2) of HF50 will be calculated.

    Time frame: Up to 2 years

07

Study locations

1 of 2 sites recruiting
  • Cancer Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100021, China
    Not yet recruiting
    • FEI MA, MD,PhD · Contact
    • FEI MA, MD,PhD · Principal investigator
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
    Recruiting
    • HERUI YAO, MD,PhD · Contactyaohrsysu@163.com · +8613500018020
    • Jing Li, MD, PhD · Principal investigator
    • Qiong Yang, MD, PhD · Principal investigator
    • HERUI YAO, MD,PhD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Jun 2028, 21 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Sep 2026, on Sep 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 22, 2026
StartActual
Sep 8, 2026was Jun 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2029
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 28, 2026
Sites
1 site added. Sun Yat-sen Memorial Hospital, Sun Yat-sen University is now Recruiting
Show site
  • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, China
Sep 28, 2026
Start date
Jun 30, 2026→Sep 8, 2026 (actual)
Sep 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University · Guangzhou, ChinaContact l•••@163.com · •••2587→y•••@163.com · •••8020Contact added (no phone or email listed)
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Not yet recruiting→Recruiting
    1 site added. Sun Yat-sen Memorial Hospital, Sun Yat-sen University is now Recruiting
    Show site
    • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, China
    Start date Jun 30, 2026→Sep 8, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Sun Yat-sen Memorial Hospital, Sun Yat-sen University · Guangzhou, ChinaContact l•••@163.com · •••2587→y•••@163.com · •••8020Contact added (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07601334
Lead sponsor
HighField Biopharmaceuticals Corporation
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Sep 8, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Sep 28, 2026

Study contacts

xun Wang
Contact
wangxun717416@gmail.com
+86-571-86961869
HERUI YAO, MD,PhD
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion